17:54 , Jan 9, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; colorectal cancer Cell culture and mouse studies suggest an SAE1 inhibitor could help treat colorectal cancers, including those with high MYC expression. In vitro screening of a small molecule library, followed by optimization...
01:34 , Jun 22, 2018 |  BC Innovations  |  Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8 + T cells have grabbed most of the attention, a study...
18:35 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma; mantle cell lymphoma (MCL) Patient sample and mouse studies suggest inhibiting the pentose phosphate pathway with PP2A inhibitor LB-100, inhibition of G6PD or synergistic combination of both,...
16:43 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Homology raises $83.5M series B

On Aug. 1, gene therapy company Homology Medicines Inc. (Lexington, Mass.) raised $83.5 million in a series B round led by Deerfield Management. Existing investors 5AM Ventures , Arch Venture Partners and Temasek also participated,...
22:53 , Aug 1, 2017 |  BC Extra  |  Financial News

Homology raises $83.5M in series B round

Gene therapy company Homology Medicines Inc. (Lexington, Mass.) raised $83.5 million in a series B round led by Deerfield Management. Existing investors 5AM Ventures , Arch Venture Partners and Temasek participated, as well as new...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting FTO or promoting METTL3 expression could help treat glioblastoma multiforme (GBM). In primary GBM stem cell-based assays of tumor formation, overexpression of METTL3 decreased growth...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting FTO or promoting METTL3 expression could help treat glioblastoma multiforme (GBM). In primary GBM stem cell-based assays of tumor formation, overexpression of METTL3 decreased growth...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ubiquitin-like modifier activating enzyme 2 (UBA2; SAE2)

Cancer INDICATION: Colorectal cancer Patient sample and cell culture studies suggest inhibiting UBA2 could help treat colorectal cancer. In tissue samples from stage II and III colorectal cancer patients, tumor levels of UBA2 were higher...
01:35 , May 3, 2016 |  BC Extra  |  Financial News

5AM incubator spinout Homology raises $43.5M

Gene editing company Homology Medicines Inc. spun out of 5AM Ventures' incubator with a $43.5 million series A round led by 5AM and Arch Venture Partners. Temasek, Deerfield and Arch Overage Fund also participated. Homology's...
07:00 , May 2, 2016 |  BioCentury  |  Emerging Company Profile

Harnessing homology

Homology Medicines Inc. is set to spin out of 5AM Ventures ' incubator this week with a $43.5 million series A round and a gene editing platform that could be the first to provide targeted...